The Impact of Vaccination Among Hospitalized Patients with the Diagnosis of COVID-19

被引:1
作者
Yildiz, Yesim [1 ]
Ozger, Hasan Selcuk [1 ]
Acar, Ali [2 ]
Seremet-Keskin, Aysegul [3 ]
Binay, Umut Devrim [4 ]
Unlu, Gulten [5 ]
Bayram, Halim [6 ]
Asan, Ali [7 ]
Akca, Mustafa Ozgur [7 ]
Karamanlioglu, Dilek [8 ]
Inan, Osman [9 ]
Kaya, Safak [10 ]
Yildirim, Cigdem [11 ]
Arslan, Yusuf [12 ]
Komur, Suheyla [13 ]
Saygideger, Yasemin [14 ]
Kandemir, Fatma Ozlem [15 ]
Yasar, Simge [15 ]
Akdemir-Kalkan, Irem [16 ]
Tekin-Tas, Zeynep [17 ]
Sakiz, Ayse [18 ]
Bayindir, Yasar [19 ]
Ozer, Ayse Belin [20 ]
Mete, Ayse Ozlem [21 ]
Erol, Cigdem [22 ]
Mermutluoglu, Cigdem [23 ]
Kadiroglu, Ali Kemal [24 ]
Azap, Alpay [16 ]
Senol, Esin [1 ]
机构
[1] Gazi Univ, Dept Infect Dis & Clin Microbiol, Sch Med, Ankara, Turkiye
[2] Atilim Univ, Dept Infect Dis & Clin Microbiol, Sch Med, Ankara, Turkiye
[3] Univ Hlth Sci, Antalya Training & Res Hosp, Dept Infect Dis & Clin Microbiol, Antalya, Turkiye
[4] Erzincan Binali Yildirim Univ, Dept Infect Dis & Clin Microbiol, Sch Med, Erzincan, Turkiye
[5] Univ Hlth Sci, Kocaeli Derince Training & Res Hosp, Dept Infect Dis & Clin Microbiol, Kocaeli, Turkiye
[6] Gaziantep Dr Ersin Arslan Tranining & Res Hosp, Dept Infect Dis & Clin Microbiol, Gaziantep, Turkiye
[7] Univ Hlth Sci, Bursa Training & Res Hosp, Dept Infect Dis & Clin Microbiol, Bursa, Turkiye
[8] Ankara City Hosp, Dept Infect Dis & Clin Microbiol, Ankara, Turkiye
[9] Ankara City Hosp, Dept Internal Med, Ankara, Turkiye
[10] Univ Hlth Sci, Diyarbakir Gazi Yasargil Training & Res Hosp, Dept Infect Dis & Clin Microbiol, Diyarbakir, Turkiye
[11] Pursaklar State Hosp, Dept Infect Dis & Clin Microbiol, Ankara, Turkiye
[12] Batman Training & Res Hosp, Dept Infect Dis & Clin Microbiol, Batman, Turkiye
[13] Cukurova Univ, Dept Infect Dis & Clin Microbiol, Sch Med, Adana, Turkiye
[14] Cukurova Univ, Dept Pulm, Sch Med, Adana, Turkiye
[15] Mersin Univ, Dept Infect Dis & Clin Microbiol, Sch Med, Mersin, Turkiye
[16] Ankara Univ, Dept Infect Dis & Clin Microbiol, Sch Med, Ankara, Turkiye
[17] Sincan Dr Nafiz Korez State Hosp, Dept Infect Dis & Clin Microbiol, Ankara, Turkiye
[18] Mardin Training & Res Hosp, Dept Infect Dis & Clin Microbiol, Mardin, Turkiye
[19] Inonu Univ, Dept Infect Dis & Clin Microbiol, Sch Med, Malatya, Turkiye
[20] Inonu Univ, Dept Anesthesiol & Reanimat, Sch Med, Malatya, Turkiye
[21] Gaziantep Univ, Dept Infect Dis & Clin Microbiol, Sch Med, Gaziantep, Turkiye
[22] Baskent Univ, Dept Infect Dis & Clin Microbiol, Sch Med, Ankara, Turkiye
[23] Dicle Univ, Dept Infect Dis & Clin Microbiol, Sch Med, Diyarbakir, Turkiye
[24] Dicle Univ, Dept Nephrol, Sch Med, Diyarbakir, Turkiye
来源
INFECTIOUS DISEASES AND CLINICAL MICROBIOLOGY | 2023年 / 5卷 / 02期
关键词
COVID-19; vaccine; intensive care unit; risk factor; SARS-CoV-2; infection; vaccine breakthrough infections; variant of concerns;
D O I
10.36519/idcm.2023.216
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Objective: We aimed to investigate the vaccination status and the risk factors for the intensive care unit (ICU) support need of the laboratory-confirmed breakthrough COVID-19 infection inpatients. Materials and Methods: This multi-center point-prevalence study was conducted on inpatients, divided into two groups as 'fully' and 'partially' vaccinated according to COVID-19 vaccination status. Results: Totally 516 patients were included in the study. The median age was 65 (55-77), and 53.5% (n=276) of the patients were male. Hypertension (41.9%, n=216), diabetes mellitus (DM) (31.8%, n=164), and coronary artery disease (CAD) (16.3%, n=84) were the predominant comorbidities. Patients were divided into two groups ICU (n=196) and non-ICU (n=301). Hypertension (p=0.026), DM (p=0.048), and congestive heart failure (CHF) (p=0.005) were significantly higher in ICU patients and the median age was younger among non-ICU patients (p=0.033). Of patients, 16.9% (n=87) were fully vaccinated, and this group's need for ICU support was statistically significantly lower (p=0.021). Conclusion: We conclude that older age, hypertension, DM, CHF, and being partially vaccinated were associated with the need for ICU support. Therefore, all countries should continuously monitor post-vaccination breakthrough COVID-19 infections to determine the national booster vaccine administration approach that will provide vulnerable individuals the highest protection.
引用
收藏
页码:118 / 126
页数:9
相关论文
共 28 条
  • [1] BNT162b2 vaccine breakthrough: clinical characteristics of 152 fully vaccinated hospitalized COVID-19 patients in Israel
    Brosh-Nissimov, Tal
    Orenbuch-Harroch, Efrat
    Chowers, Michal
    Elbaz, Meital
    Nesher, Lior
    Stein, Michal
    Maor, Yasmin
    Cohen, Regev
    Hussein, Khetam
    Weinberger, Miriam
    Zimhony, Oren
    Chazan, Bibiana
    Najjar, Ronza
    Zayyad, Hiba
    Rahav, Galia
    Wiener-Well, Yonit
    [J]. CLINICAL MICROBIOLOGY AND INFECTION, 2021, 27 (11) : 1652 - 1657
  • [2] CDC, Interim clinical considerations for use of COVID-19 vaccines in the United States
  • [3] CDC, Stay Up To Date with COVID-19 Vaccines Including Boosters.
  • [4] cdc, ACIP vaccine recommendations and guidelines: Advisory Committee on Immunization Practices (ACIP)
  • [5] Efficacy and Safety of COVID-19 Vaccines in Phase III Trials: A Meta-Analysis
    Cheng, Haoyue
    Peng, Zhicheng
    Luo, Wenliang
    Si, Shuting
    Mo, Minjia
    Zhou, Haibo
    Xin, Xing
    Liu, Hui
    Yu, Yunxian
    [J]. VACCINES, 2021, 9 (06)
  • [6] covid19treatmentguidelines.nih.gov, COVID-19 Treatment Guidelines Panel Coronavirus Disease 2019 (COVID-19) Treatment Guidelines
  • [7] Vaccine Breakthrough Infections with SARS-CoV-2 Variants
    Hacisuleyman, Ezgi
    Hale, Caryn
    Saito, Yuhki
    Blachere, Nathalie E.
    Bergh, Marissa
    Conlon, Erin G.
    Schaefer-Babajew, Dennis J.
    DaSilva, Justin
    Muecksch, Frauke
    Gaebler, Christian
    Lifton, Richard
    Nussenzweig, Michel C.
    Hatziioannou, Theodora
    Bieniasz, Paul D.
    Darnell, Robert B.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (23) : 2212 - 2218
  • [8] Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection
    Khoury, David S.
    Cromer, Deborah
    Reynaldi, Arnold
    Schlub, Timothy E.
    Wheatley, Adam K.
    Juno, Jennifer A.
    Subbarao, Kanta
    Kent, Stephen J.
    Triccas, James A.
    Davenport, Miles P.
    [J]. NATURE MEDICINE, 2021, 27 (07) : 1205 - +
  • [9] Risk Factors Associated With SARS-CoV-2 Breakthrough Infections in Fully mRNA-Vaccinated Individuals: Retrospective Analysis
    Liu, Cong
    Lee, Junghwan
    Ta, Casey
    Soroush, Ali
    Rogers, James R.
    Kim, Jae Hyun
    Natarajan, Karthik
    Zucker, Jason
    Perl, Yehoshua
    Weng, Chunhua
    [J]. JMIR PUBLIC HEALTH AND SURVEILLANCE, 2022, 8 (05):
  • [10] Covid-19: How many variants are there, and what do we know about them?
    Mahase, Elisabeth
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2021, 374